Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
2.
Neuromuscul Disord ; 28(3): 278-282, 2018 03.
Article in English | MEDLINE | ID: mdl-29395672

ABSTRACT

DOK7 congenital myasthenic syndrome (DOK7-CMS) generally presents early in life and is treated with salbutamol or ephedrine. This report describes an atypical case of a 39-year-old woman who presented with proximal upper limb weakness in the third trimester of pregnancy and was initially diagnosed with seronegative myasthenia gravis. Dramatic clinical worsening under pyridostigmine and further inefficacy of steroids, intravenous human immunoglobulin (IVIG) and plasma exchange (PLEX) led to the presumptive diagnosis of a CMS. Initially, a slow-channel CMS was regarded as more probable due to prominent finger extension weakness. Accordingly, fluoxetine was started and a lengthy improvement was seen. Clinical deterioration occurred after fluoxetine withdrawal, when a c.1124_1127dup homozygous mutation was detected in DOK7 gene. Afterwards, salbutamol was started and the patient became asymptomatic. This case highlights the importance of considering CMS before an adult-onset myasthenic syndrome and suggests a benefit from fluoxetine not previously reported in DOK7-CMS.


Subject(s)
Fluoxetine/therapeutic use , Muscle Proteins/genetics , Muscle Weakness/genetics , Myasthenic Syndromes, Congenital/genetics , Adult , Female , Humans , Muscle Weakness/drug therapy , Myasthenic Syndromes, Congenital/drug therapy , Pregnancy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...